INT55367

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.70
First Reported 1994
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 18
Total Number 18
Disease Relevance 7.43
Pain Relevance 0.38

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (Dbp)
Anatomy Link Frequency
BAT 1
inferior 1
14.2 1
Dbp (Rattus norvegicus)
Pain Link Frequency Relevance Heat
beta blocker 20 90.52 High High
antagonist 58 86.32 High High
agonist 5 75.00 Quite High
Bioavailability 2 67.12 Quite High
headache 22 64.96 Quite High
Inflammation 16 56.24 Quite High
anesthesia 5 50.00 Quite Low
Cannabinoid receptor 3 50.00 Quite Low
Ultiva 2 50.00 Quite Low
Opioid 2 50.00 Quite Low
Disease Link Frequency Relevance Heat
Ocular Toxicity (including Many Sub-types) 7 100.00 Very High Very High Very High
Nicotine Addiction 10 99.96 Very High Very High Very High
Obesity 18 99.68 Very High Very High Very High
Hypertension 471 99.24 Very High Very High Very High
Diabetes Mellitus 107 99.04 Very High Very High Very High
Neuropathy 68 97.72 Very High Very High Very High
Adverse Drug Reaction 4 92.96 High High
Stress 36 89.44 High High
Metabolic Syndrome 14 86.56 High High
Pressure And Volume Under Development 39 84.40 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The decrease in SBP and DBP at each follow-up visit compared with baseline was statistically significant both in the intergroup and intragroup comparisons (p < 0.001, one-way ANOVA).
Localization (decrease) of DBP
1) Confidence 0.70 Published 2006 Journal International Journal of Clinical Practice Section Body Doc Link PMC1636683 Disease Relevance 0.30 Pain Relevance 0
KEY RESULTS: In anaesthetized rats, anandamide (1.5-3 micromol.kg(-1)) and its stable analogue methanandamide (0.5 micromol.kg(-1)) caused a delayed and prolonged decrease in MBP, SBP, DBP, MBF and RBF by about 10-30% of the respective basal values without changing HR.
Localization (decrease) of DBP
2) Confidence 0.68 Published 2010 Journal Br. J. Pharmacol. Section Body Doc Link 20105178 Disease Relevance 0.08 Pain Relevance 0
Isoproterenol at doses of 0.01-1 microgram/kg (i.v.) dose-dependently increased HR and BAT blood flow and decreased DBP.
Localization (decreased) of DBP in BAT associated with obesity
3) Confidence 0.66 Published 1994 Journal Clin. Exp. Pharmacol. Physiol. Section Abstract Doc Link 7982286 Disease Relevance 0.78 Pain Relevance 0.11
In addition, the percentage of patients responding to therapy (>10 mmHg decrease from baseline) is higher in patients receiving combination therapy than in those receiving mono-therapy, and decreases from baseline in both DBP and SBP are dose related.
Localization (decreases) of DBP
4) Confidence 0.41 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2663442 Disease Relevance 0.36 Pain Relevance 0
Both DBP and SBP were measured at weeks 4, 8, and 12 of each study.
Localization (measured) of DBP
5) Confidence 0.41 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2663442 Disease Relevance 0.17 Pain Relevance 0
MAIN RESULTS: Logistic correlation coefficient values for SBP and DBP decreases were larger than the cubic correlation coefficient values (0.990 [Z transformation: 2.64 +/- 0.32] vs 0.981 [Z: 2.32 +/- 0.37] and 0.977 [Z: 2.22 +/- 0.33] vs 0.967 [Z: 2.05 +/- 0.34], respectively; P < 0.05).
Localization (decreases) of DBP
6) Confidence 0.40 Published 2007 Journal J Clin Anesth Section Body Doc Link 18063203 Disease Relevance 0 Pain Relevance 0
The effect of adding either 12.5 mg or 25 mg HCTZ to olmesartan 20 mg on ABPM in patients whose DBP (measured by standard mercury sphygmomanometer) continued to be ?
Localization (measured) of DBP
7) Confidence 0.36 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2663442 Disease Relevance 0.25 Pain Relevance 0
Different primary end points were defined in these studies: the reduction in DBP, either from baseline (Karlberg et al 1999; Lacourciére et al 2001; McGill and Reilly 2001b; Lacourciére and Martin 2002; Freytag et al 2002) or to values inferior to 90 mmHg (Neutel et al 2002; Freytag et al 2002); changes in ambulatory DBP and SBP (Lacourciére et al 2003); and decreases in supine SBP (Karlberg et al 1999; Freytag et al 2001).
Localization (decreases) of DBP in inferior
8) Confidence 0.35 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2293961 Disease Relevance 0 Pain Relevance 0
In the trial reported by Oparil and colleagues (2001), 588 patients with a mean cuff DBP of 100–115 mmHg and ambulatory daytime DBP ?
Localization (daytime) of DBP
9) Confidence 0.19 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994016 Disease Relevance 0 Pain Relevance 0.04
The initial results indicate that olmesartan 20 mg was the most frequently prescribed dose and that after 12 weeks of treatment the mean decrease from baseline was 28.4 mmHg SBP and 14.2 mmHg for DBP (Scholze and Ewald 2005).
Localization (decrease) of DBP in 14.2
10) Confidence 0.19 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994016 Disease Relevance 0.16 Pain Relevance 0
As expected, in all exercise protocols and in both groups, SBP and DBP increased significantly during the exercise sets and decreased during the rest periods.
Localization (decreased) of DBP
11) Confidence 0.15 Published 2010 Journal Clinics (Sao Paulo) Section Body Doc Link PMC2845767 Disease Relevance 0.24 Pain Relevance 0
In this study the key factor to predict normalization of both SBP and DBP was the severity of hypertension.
Localization (normalization) of DBP associated with hypertension
12) Confidence 0.13 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1993978 Disease Relevance 1.34 Pain Relevance 0.06
Variation of SBP and DBP were similar for men and women.
Localization (Variation) of DBP
13) Confidence 0.11 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1993978 Disease Relevance 0.85 Pain Relevance 0.06
The target of SBP <140 mmHg and DBP <90 mmHg was achieved at week 4 by 1267 patients (42.9%) and at week 8 by 1865 patients (65.5%) (Figure 1).
Localization (target) of DBP
14) Confidence 0.11 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1993978 Disease Relevance 0.40 Pain Relevance 0.05
At 30 minutes afterincision, MBP and DBP returned to basal levels in the DEX group, whereas the variables were significantly lower in the REM group.
Localization (returned) of DBP
15) Confidence 0.10 Published 2007 Journal J Clin Anesth Section Body Doc Link 17572323 Disease Relevance 0 Pain Relevance 0
In addition, smoking, retinopathy, SBP, DBP, serum AST, CRP, and urinary ACR also showed significant associations as risk factors of DPP (P < 0.05, Tables 3 and 4).
Localization (retinopathy) of DBP associated with neuropathy, nicotine addiction and ocular toxicity (including many sub-types)
16) Confidence 0.07 Published 2010 Journal Korean Diabetes Journal Section Body Doc Link PMC2883349 Disease Relevance 2.36 Pain Relevance 0.06
However, approximately 30% of patients did not achieve DBP normalization and went on to receive randomized treatment.
Localization (normalization) of DBP
17) Confidence 0.05 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2742702 Disease Relevance 0.08 Pain Relevance 0
Patients whose DBP was not normalized (ie, ?
Neg (not) Localization (normalized) of DBP
18) Confidence 0.05 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2742702 Disease Relevance 0.08 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox